Retatrutide, a experimental dual activator of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) binding site , is exhibiting promising results in early patient trials . Current https://bookmarkquotes.com/story21493194/retatrutide-emerging-studies-and-possible-clinical-uses